Landolfo Santo, De Andrea Marco, Dell'Oste Valentina, Gugliesi Francesca
Santo Landolfo, Marco De Andrea, Valentina Dell'Oste, Francesca Gugliesi, Department of Public Health and Pediatric Sciences, Laboratory of Pathogenesis of Viral Infections, University of Turin, 10126 Turin, Italy.
World J Virol. 2016 Aug 12;5(3):87-96. doi: 10.5501/wjv.v5.i3.87.
Before a pathogen even enters a cell, intrinsic immune defenses are active. This first-line defense is mediated by a variety of constitutively expressed cell proteins collectively termed "restriction factors" (RFs), and they form a vital element of the immune response to virus infections. Over time, however, viruses have evolved in a variety ways so that they are able to overcome these RF defenses via mechanisms that are specific for each virus. This review provides a summary of the universal characteristics of RFs, and goes on to focus on the strategies employed by some of the most important RFs in their attempt to control human cytomegalovirus (HCMV) infection. This is followed by a discussion of the counter-restriction mechanisms evolved by viruses to circumvent the host cell's intrinsic immune defenses. RFs include nuclear proteins IFN-γ inducible protein 16 (IFI16) (a Pyrin/HIN domain protein), Sp100, promyelocytic leukemia, and hDaxx; the latter three being the keys elements of nuclear domain 10 (ND10). IFI16 inhibits the synthesis of virus DNA by down-regulating UL54 transcription - a gene encoding a CMV DNA polymerase; in response, the virus antagonizes IFI16 via a process involving viral proteins UL97 and pp65 (pUL83), which results in the mislocalizing of IFI16 into the cytoplasm. In contrast, viral regulatory proteins, including pp71 and IE1, seek to modify or disrupt the ND10 proteins and thus block or reverse their inhibitory effects upon virus replication. All in all, detailed knowledge of these HCMV counter-restriction mechanisms will be fundamental for the future development of new strategies for combating HCMV infection and for identifying novel therapeutic agents.
在病原体进入细胞之前,固有免疫防御就已激活。这种一线防御由多种组成性表达的细胞蛋白介导,这些蛋白统称为“限制因子”(RFs),它们构成了针对病毒感染的免疫反应的重要组成部分。然而,随着时间的推移,病毒通过多种方式进化,从而能够通过针对每种病毒的特定机制克服这些RF防御。本综述总结了RFs的普遍特征,并继续聚焦于一些最重要的RFs在试图控制人巨细胞病毒(HCMV)感染时所采用的策略。接下来讨论病毒为规避宿主细胞固有免疫防御而进化出的反限制机制。RFs包括核蛋白γ干扰素诱导蛋白16(IFI16)(一种含pyrin/HIN结构域的蛋白)、Sp100、早幼粒细胞白血病蛋白和hDaxx;后三种是核结构域10(ND10)的关键成分。IFI16通过下调UL54转录来抑制病毒DNA的合成,UL54是一种编码CMV DNA聚合酶的基因;作为回应,病毒通过涉及病毒蛋白UL97和pp65(pUL83)的过程对抗IFI16,这导致IFI16错误定位到细胞质中。相比之下,包括pp71和IE1在内的病毒调节蛋白试图修饰或破坏ND10蛋白,从而阻断或逆转它们对病毒复制的抑制作用。总而言之,详细了解这些HCMV反限制机制对于未来开发对抗HCMV感染的新策略以及识别新型治疗药物至关重要。